MEI Pharma (NASDAQ:MEIP) Issues Earnings Results

MEI Pharma (NASDAQ:MEIP) announced its quarterly earnings data on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, Zacks reports.

MEI Pharma Stock Down 1.5 %

MEIP stock traded down $0.04 during trading on Wednesday, reaching $2.66. The company’s stock had a trading volume of 2,534 shares, compared to its average volume of 11,683. The company’s fifty day moving average is $2.68 and its 200-day moving average is $2.90. MEI Pharma has a 1 year low of $2.30 and a 1 year high of $4.90. The company has a market capitalization of $17.72 million, a P/E ratio of -0.38 and a beta of 0.79.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on MEI Pharma in a research note on Tuesday. They set a “buy” rating on the stock.

About MEI Pharma

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.